3C
CTMX icon

361 Capital’s CytomX Therapeutics CTMX Stock Holding History

361 Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$671K Buy
+80,556
New +$748K 0.31% 169

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

361 Capital's CTMX Position: Q2 2020 in Review

361 Capital opened a new position in CytomX Therapeutics (CTMX) in Q2 2020: 80,556 shares worth $671K. The stake represents 0.31% of the portfolio and ranks #169 among its holdings.

134 funds tracked by Wall St. Rank hold CTMX as of Q2 2020.

  • 361 Capital held 80,556 shares of CytomX Therapeutics worth $671K as of Q2 2020.
  • CytomX Therapeutics was a new 361 Capital position in Q2 2020.
  • CytomX Therapeutics made up 0.31% of 361 Capital's portfolio in Q2 2020, its #169 holding.
  • 134 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.